ライフサイエンスコーパス: fluoxetine

1 d 250 mg of imipramine equivalents (50 mg of fluoxetine).

2 stress and the effects of the antidepressant fluoxetine.

3 were found to be the key residues in binding fluoxetine.

4 in regulation of BDNF expression induced by fluoxetine.

5 vely influenced by postnatal, but not adult, fluoxetine.

6 ent the behavioral and neurogenic effects of fluoxetine.

7 s and reversed by systemic administration of fluoxetine.

8 f the selective serotonin reuptake inhibitor fluoxetine.

9 Both changes were reversed by chronic fluoxetine.

10 C optogenetic stimulation and is reversed by fluoxetine.

11 elective serotonin reuptake inhibitor (SSRI) fluoxetine.

12 nin reuptake inhibitor (SSRI) antidepressant fluoxetine.

13 tment with the front-line anxiety medication fluoxetine.

14 BDNF in hippocampus suppressed the effect of fluoxetine.

15 the selective serotonin reuptake inhibitor, fluoxetine.

16 ement in the sensitivity of the electrode to fluoxetine.

17 th injections, and chronic SSRI with dietary fluoxetine.

18 ng the reproductive phenotype attained under fluoxetine.

19 GR signalling and the therapeutic action of fluoxetine.

20 progeny of WT dams given the SERT antagonist fluoxetine.

21 of type I NSCs was unchanged in response to fluoxetine.

22 reatment with desipramine (50-200 mg/day) or fluoxetine (10-40 mg/day) after a 1-week placebo lead-in

23 Fluoxetine (18 mg/kg/day) increased food intake and redu

24 Of these, 115 patients were taking fluoxetine (20 mg/day) for >/=2 months, and 121 patients

25 e; oral gavage); and 3) rats with ligature + fluoxetine (20 mg/kg/day in saline; oral gavage).

26 (N=8) of each group was randomly assigned to fluoxetine (3 mg/kg) or placebo for 1 year.

27 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated impr

28 luated the effects of chronic treatment with fluoxetine (4 weeks) or subchronic treatment with olanza

29 ceive 3 weeks of oral dosing with placebo or fluoxetine, 40 mg per day.

30 with either agomelatine (40 mg/kg, i.p.) or fluoxetine (5 mg/kg, i.p.) for 21 d.

31 long-term treatment with the antidepressants fluoxetine (5 mg/kg/day) and desipramine (10 mg/kg/day),

32 the selective serotonin reuptake inhibitor, fluoxetine (5 or 25 mg/L), commonly known as Prozac(R),

33 n obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%).

34 genetic deletion of Slc6a4 or treatment with Fluoxetine, a 5-HT reuptake inhibitor, restored normal b

35 g and evoked firing were reversed by chronic fluoxetine, a first-line OCD treatment.

36 Follow-up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SS

37 atment of traumatized IF-CCKR-2 tg mice with fluoxetine, a selective serotonin reuptake inhibitor, fo

38 Fluoxetine, a selective serotonin reuptake inhibitor, ha

39 Fluoxetine, a selective serotonin reuptake inhibitor, ha

40 to quantify uptake and biological effects of fluoxetine, a selective serotonin reuptake inhibitor, in

41 vestigated the Nav1.5 blocking properties of fluoxetine, a selective serotonin reuptake inhibitor.

42 Long-term treatment of Hoxb8 mutants with fluoxetine, a serotonin reuptake inhibitor, reduces exce

43 Infusion of fluoxetine, a serotonin uptake inhibitor, increased dial

44 ltered through the chronic administration of fluoxetine, a treatment that also facilitates retention

45 Fluoxetine administered to juvenile monkeys upregulates

46 This study examined the long-term effects of fluoxetine administered to juvenile rhesus monkeys who,

47 f Behavioral Neuroscience entitled "Repeated Fluoxetine Administration During Adolescence Stimulates

48 examined the effects of repeated adolescent fluoxetine administration on offensive aggression and th

49 ue sampled 3 days after ligature attachment, fluoxetine administration reduced IL-1beta and COX-2 mRN

50 Unexpectedly, Fluoxetine administration was associated with respirator

51 not significantly more durable than those of fluoxetine after treatment was stopped, suggesting that

52 be taken into consideration when prescribing fluoxetine alone or in association with other drugs that

53 Administration of fluoxetine also increased AChE activity throughout the b

54 Fluoxetine also resulted in significantly less anxiety a

55 n removal in septal subregions, whereas both fluoxetine and a dopamine transporter blocker depress re

56 ped dramatically after 2002, while rates for fluoxetine and amitriptyline remained stable.

57 ry indicated that the observed uptake in the fluoxetine and carbamazepine treatments was due to the p

58 BT, fluoxetine, or joint treatment with both fluoxetine and CBT.

59 SERT Met172 mice are insensitive to chronic fluoxetine and citalopram administration in the novelty

60 n the tail suspension and forced swim tests, fluoxetine and citalopram fail to reduce immobility in S

61 the actions of two widely prescribed SSRIs, fluoxetine and citalopram, in tests sensitive to acute a

62 good-quality studies of fluoxetine, combined fluoxetine and cognitive behavioral therapy, escitalopra

63 Fluoxetine and desipramine reversed lower, but not highe

64 The authors compared the effectiveness of fluoxetine and desipramine treatment in a prospective do

65 ions and reasonable predictions of uptake of fluoxetine and diclofenac from a sediment.

66 Fluoxetine and EE2 alone did not affect estrogen recepto

67 the selective serotonin reuptake inhibitors fluoxetine and escitalopram.

68 of 15000 total probes) exposed to two SSRIs (fluoxetine and fluvoxamine) or to 4-nonylphenol.

69 geriatric patients, and 708 youths receiving fluoxetine and for 2421 adults receiving immediate-relea

70 elective serotonin reuptake inhibitor (SSRI) fluoxetine and had improved latency for its therapeutic

71 y reduced primary anxiety symptoms more than fluoxetine and improved remission more than sertraline.

72 DIVS6) significantly reduced the affinity of fluoxetine and its frequency-dependent inhibition.

73 Fluoxetine and its metabolite norfluoxetine both inhibit

74 orfluoxetine, we investigated the effects of fluoxetine and its metabolite norfluoxetine on IKs.

75 Fluoxetine and N-desmethyl citalopram were the most rapi

76 We find that the selectivity of fluoxetine and nisoxetine, a NET selective structural co

77 ed in the order carbamazepine < diclofenac < fluoxetine and orlistat.

78 and attended more sessions than those in the fluoxetine and PBO groups.

79 The effects of fluoxetine and placebo on repetitive behaviors and globa

80 evaluated a sequential treatment strategy of fluoxetine and relapse-prevention cognitive-behavioral t

81 We further demonstrate that the SSRIs, fluoxetine and sertraline, directly suppress TIDA neuron

82 We first determined that the SSRI fluoxetine and the nicotinic partial agonist cytisine ha

83 The 5-HT uptake inhibitor fluoxetine and the norepinephrine uptake inhibitor desip

84 Both fluoxetine and thioridazine inhibited efflux in P. mirab

85 al for drugs already used in human medicine (fluoxetine and thioridazine) to act as EPIs in P. mirabi

86 l agents, including duloxetine, atomoxetine, fluoxetine and tolterodine.

87 The antidepressants fluoxetine and venlafaxine are efficacious for major dep

88 or-conducted randomized controlled trials of fluoxetine and venlafaxine.

89 oach for two pharmaceuticals (diclofenac and fluoxetine) and one personal care product ingredient (tr

90 uman intravenous immunoglobulin (hIVIG), (2) fluoxetine, and (3) dexamethasone.

91 Furthermore, escitalopram, fluoxetine, and cocaine induced a very similar pattern o

92 The drugs diclofenac, fluoxetine, and gemfibrozil belong to different pharmace

93 data are needed on the uptake of cimetidine, fluoxetine, and gemfibrozil, and other ionizable PPCPs,

94 of (14)C-labeled carbamazepine, diclofenac, fluoxetine, and orlistat in soil-earthworm systems.

95 ortisone, IgG, valganciclovir, isoprinosine, fluoxetine, and various complementary medicines were inc

96 selective reuptake inhibitor antidepressant, fluoxetine; and social defeat stress.

97 However, unlike fluoxetine, anxiolytic effects of RS67333 were already p

98 Fluoxetine appeared to be well tolerated.

99 e effects of chronic treatment with the SSRI fluoxetine at clinically relevant serum concentrations o

100 of a local wastewater treatment plant where fluoxetine, atorvastatin, and sertraline were detected i

101 We show that fluoxetine binds within the central substrate site of hu

102 We concluded that fluoxetine blocks Nav1.5 by binding to the class 1 antia

103 easure revealed that, compared with placebo, fluoxetine (but not CBT) was significantly more effectiv

104 behavioral and molecular effects of chronic fluoxetine, but there was no additive effect of CR in fl

105 truction of collagen fibers, suggesting that fluoxetine can constitute a promising therapeutic approa

106 tion in the spiked plasma samples as well as fluoxetine capsules.

107 dol, sertindole, clotiapine, phenothiazines, fluoxetine, citalopram (including escitalopram), and met

108 In contrast to fluoxetine, citalopram treatment did not increase BLA eC

109 ases following acute treatment with typical (fluoxetine, citalopram, reboxetine, venlafaxine, clomipr

110 hort-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), quetiapine, and risperidon

111 resistant depression (TRD) taking olanzapine/fluoxetine combination (OFC).

112 n (SD) changes in MADRS score for the light, fluoxetine, combination, and placebo groups were 13.4 (7

113 individual fair- and good-quality studies of fluoxetine, combined fluoxetine and cognitive behavioral

114 orticosterone-pretreated mice in response to fluoxetine compared with the corresponding group of vehi

115 Embryos treated with fluoxetine continued to exhibit abnormal behavior upto 1

116 In the process, we confirmed that fluoxetine could improve the depression-like behaviors o

117 Fluoxetine decreased immobility in the forced swim test,

118 caine underwent a 6-week dosing regimen with fluoxetine designed to approximate serum concentrations

119 The antidepressants fluoxetine, desipramine and ketamine increased PKMzeta e

120 This sensor was used successfully for fluoxetine determination in the spiked plasma samples as

121 es following the discontinuation of C-CT and fluoxetine did not differ.

122 a noninactivating Nav1.5 mutant to show that fluoxetine displays open-channel block behavior.

123 Fluoxetine does not affect the overall transcription of

124 ed exposure to a low dose (0.3 mg/kg/day) of fluoxetine during adolescence increased nearly all measu

125 this journal shows that exposure to low-dose fluoxetine during adolescence predisposes Syrian hamster

126 ministration of clinically relevant doses of fluoxetine during adolescent development directly stimul

127 Postnatal fluoxetine-evoked anxiety and depressive behavior, as we

128 h the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety and depressive behavior in ro

129 mergence of perturbed emotionality following fluoxetine exposure in early life.

130 inhibition of CaMKII activity in NAc mimics fluoxetine exposure.

131 Behaviorally, chronic fluoxetine facilitated extinction retrieval in a manner

132 s revealed that, while degradation of chiral fluoxetine (FL) in river water occurs via non-enantiosel

133 The antidepressant fluoxetine (FLX) and the synthetic estrogen, 17 alpha-et

134 f the selective-serotonin reuptake inhibitor fluoxetine (FLX) in a chronic unpredictable stress model

135 nd studied the effects of the antidepressant fluoxetine (FLX) on behavior, olfaction, and adult neuro

136 n contrast, the serotonin reuptake inhibitor fluoxetine (FLX) reduced immobility after 14, but not 5

137 , we examined whether adolescent exposure to fluoxetine (FLX), a selective serotonin reuptake inhibit

138 ssessed the long-term effects of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibit

139 We show here that fluoxetine (Flx), one of the most-prescribed SSRIs, acts

140 elective serotonin reuptake inhibitor (SSRI) fluoxetine (FLX), the active ingredient of the antidepre

141 del of psychosocial stress, and prevents the fluoxetine (FLX)-induced reversal of SDS-induced social

142 th major depression were treated openly with fluoxetine for 6 weeks.

143 A single trial of fluoxetine for chronic daily headaches found it ineffect

144 ports the safety, tolerance, and efficacy of fluoxetine for hypochondriasis.

145 ho remained stable were randomized to OFC or fluoxetine for up to 27 weeks.

146 Furthermore, fluoxetine gave rise to a change in neuropsychology.

147 group, alveolar bone loss was reduced in the fluoxetine group (P <0.05), and the amount of collagen f

148 nificantly more responders at week 12 in the fluoxetine group than in the placebo group.

149 As predicted, the C-CT or fluoxetine groups were significantly less likely to rela

150 d 10 mumol/L; order of potency: sertraline > fluoxetine > paroxetine > fluvoxamine > citalopram.

151 hole-brain voxel-wise analysis revealed that fluoxetine had a significant effect in the lateral tempo

152 Fluoxetine had no effect on motor impairment or viral lo

153 campus of naive Sprague-Dawley rats, whereas fluoxetine had no effects.

154 Fluoxetine had no significant effect on the behavioral m

155 Fluoxetine, however, suppresses the stress-induced upreg

156 nded release (with doses of up to 300 mg) or fluoxetine hydrochloride (with doses of up to 80 mg).

157 for 3001-4500 mg compared with 1-1500 mg in fluoxetine hydrochloride dose equivalents).

158 ride, lidocaine hydrochloride, diazepam, and fluoxetine hydrochloride that meet U.S. Pharmacopeia sta

159 ive negative ion generator for 30 min/d plus fluoxetine hydrochloride, 20 mg/d); (3) combination ligh

160 oxetine hydrochloride, escitalopram oxalate, fluoxetine hydrochloride, mirtazapine, nortriptyline hyd

161 Dose-response curves of racemic fluoxetine (IC50 = 39 muM) and its optical isomers had a

162 mine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortrip

163 find that retreatment of PNFlx animals with fluoxetine in adulthood reversed the increased Hdac4 exp

164 Relapse risk was reduced by both C-CT and fluoxetine in an enriched randomization sampling only CT

165 tonin reuptake inhibitors (SSRIs) other than fluoxetine in children, due to a possible increased risk

166 t as a racemic mixture, which is typical for fluoxetine in dispensed formulations.

167 rences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse

168 The molecular model of fluoxetine in Nav1.5 was in agreement with mutational ex

169 irregularly high load of the antidepressant fluoxetine in raw wastewater (10.5 +/- 2.4 g d(-1)) was

170 d and more persistent efficacy compared with fluoxetine in recovering "depressive-like" behaviors.

171 Our research highlighted the importance of fluoxetine in regulating BDNF expression which could rep

172 Blocking platelet serotonin uptake with fluoxetine in WT mice reduced serum serotonin by > 80% a

173 Further, because systemically administered fluoxetine increased aggression in females and substanti

174 osure to serotonin or the reuptake inhibitor fluoxetine increased runx1 expression and Flk1(+)/cMyb(+

175 Fluoxetine increases serotonin-immunoreactivity at low f

176 ntidepressant-like and neurogenic effects of fluoxetine, indicating that 5-HT(4) receptor activation

177 nctional 5HT1ARs only in DG GCs responded to fluoxetine, indicating that 5HT1ARs in DG GCs are suffic

178 Chronic treatment with RS67333, similar to fluoxetine, induced anxiolytic/antidepressant-like activ

179 evelopment within the LAH correlate with the fluoxetine-induced aggressive behavioral phenotype.

180 electrophysiological recordings showed that fluoxetine-induced increases in anandamide were associat

181 The SSRI fluoxetine induces expression of p11 in both cell types

182 mechanism of antidepressant action, whereby fluoxetine induces some chromatin change at the CaMKIIal

183 Fluoxetine inhibited currents in a frequency-dependent m

184 and negative correlation between duration of fluoxetine intake and attachment loss (AL) (R(2) = -0.32

185 ent study is to investigate the influence of fluoxetine intake on periodontal parameters in patients

186 Logistic regression analysis revealed that fluoxetine intake was associated with a lower risk of ha

187 hat reversal of the neurogenic deficit using fluoxetine is associated with reversal of the learning d

188 Furthermore, as fluoxetine is prescribed as one capsule per day, disposa

189 Fluoxetine is probably the best option to consider when

190 However, the binding orientation of fluoxetine is reversed in our experimentally supported m

191 Fluoxetine is widely used to treat depression, including

192 tine, a NET selective structural congener of fluoxetine, is controlled by residues in different regio

193 For the respective placebo, fluoxetine, light, and combination groups at the end poi

194 prescription data revealed a predicted daily fluoxetine load for the studied treatment works to be 0.

195 in the order of carbamazepine < diclofenac < fluoxetine < orlistat.

196 Recent work has shown that fluoxetine may exert an antidepressive effect through in

197 Studies suggest that fluoxetine may have adverse effects on offspring, presum

198 Fluoxetine may not be useful for treatment of ongoing co

199 cause the apneas in Necdin-KO pups, and that fluoxetine may offer therapeutic benefits to PWS patient

200 Norfluoxetine, a fluoxetine metabolite, had a higher affinity than fluoxe

201 or to placebo in the MADRS change score, but fluoxetine monotherapy (d = 0.24; 95% CI, -0.27 to 0.74)

202 ents were randomized (light monotherapy, 32; fluoxetine monotherapy, 31; combination therapy, 29; pla

203 ciated with continuing treatment with OFC or fluoxetine must be done based on individual patient need

204 omized to receive 8 months of C-CT (n = 86), fluoxetine (n = 86), or PBO (n = 69).

205 Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15).

206 tients were randomized 1:1 to OFC (N=221) or fluoxetine (N=223).

207 erotonin reuptake inhibitors (SSRIs) such as fluoxetine ((+/-)-N-methyl-gamma-[4-(trifluoromethyl)phe

208 ects of sustained administration of the SSRI fluoxetine on 5-HT(1A) autoreceptor sensitivity in mice

209 G GCs and found that the effects of the SSRI fluoxetine on behavior and the hypothalamic-pituitary-ad

210 CBs in mediating the facilitatory effects of fluoxetine on fear extinction has not been established.

211 he present study investigates the effects of fluoxetine on inflammatory tissue destruction in a rat m

212 There was no significant effect of fluoxetine on P-gp function, in vitro or in vivo.

213 verexpression of BMP4 blocked the effects of fluoxetine on proliferation in the dentate gyrus and on

214 Our study showed that the effect of fluoxetine on proliferation is dependent upon the type a

215 1A) recapitulated or abolished the effect of fluoxetine on proliferation of type II NSCs and neurobla

216 Fluoxetine, one of the selective serotonin reuptake inhi

217 ive 5-HT reuptake inhibitors (SSRIs) such as fluoxetine or escitalopram inhibit SERT and are currentl

218 STN DBS were prevented by pretreatment with fluoxetine or fenfluramine, the ability of DBS to suppre

219 n ([(3)H] digoxin), was co-administered with fluoxetine or sertraline to determine if either compound

220 (SL) baboons administered the antidepressant fluoxetine or vehicle.

221 gned to one of four treatments-placebo, CBT, fluoxetine, or joint treatment with both fluoxetine and

222 ders at higher risk were randomized to C-CT, fluoxetine, or PBO); and 24 months of longitudinal, post

223 n6 beta cell line with the SSRIs paroxetine, fluoxetine, or sertraline inhibited insulin-induced Tyr

224 e significantly lower in participants taking fluoxetine (P <0.01).

225 based sensitivity likely as a consequence of fluoxetine partitioning to sediment.

226 Fluoxetine persistently upregulated SERT, but not 5-HT1A

227 Paradoxically, postnatal fluoxetine (PNFlx) induces persistent depression- and an

228 in the behavioral consequences of postnatal fluoxetine (PNFlx).

229 The conventional antidepressant fluoxetine produces rapid or delayed antidepressant effe

230 with norfluoxetine, the active metabolite of fluoxetine (Prozac) and a state-dependent blocker of TRE

231 dult behavioral changes resulting from early fluoxetine (Prozac) exposure were different from those o

232 and radiopharmaceuticals including Claritin, fluoxetine (Prozac), and [(18) F]DAA1106 were synthesize

233 ortex are suppressed by therapeutic doses of fluoxetine (Prozac).

234 NET for the prototypical antidepressant drug fluoxetine (Prozac; Eli Lilly, Indianapolis, IN).

235 Indeed, chronic fluoxetine reduces acetylation and increases lysine-9 di

236 ally, chronic exposure to the antidepressant fluoxetine reduces binding of DeltaFosB to the CaMKIIalp

237 report for the first time that OLZ, but not fluoxetine, reduces ABA in mice.

238 n young adult-born GCs (abGCs) showed normal fluoxetine responses.

239 Importantly, the antidepressant fluoxetine restores both adult neurogenesis and depressi

240 , we demonstrate that chronic treatment with fluoxetine reverses several of the circuit alterations o

241 of pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam).

242 Overexpression of CaMKII in NAc blocks fluoxetine's antidepressant effects in the chronic socia

243 possible mechanistic contribution of eCBs to fluoxetine's proextinction effects, we integrated bioche

244 aste electrode (CPE) in order to construct a fluoxetine selective sensor.

245 provide strong evidence that exogenous SSRI fluoxetine selectively increases serotonin-immunoreactiv

246 The serotonin reuptake inhibitor fluoxetine selectively suppresses serotonin removal in s

247 All test drugs evoke fluoxetine-sensitive efflux of [(3)H]5-HT from synaptoso

248 es voltage-clamped to -60 mV, APP(+) induced fluoxetine-sensitive hSERT-mediated inward currents, ind

249 oblast populations specifically responded to fluoxetine, showing increased proliferation; however, pr

250 Treatment of zebrafish embryos with fluoxetine significantly blocked the expression of multi

251 The high dose of fluoxetine significantly decreased anxiety-like behaviou

252 Fluoxetine specifically increased proliferation of NSCs

253 of two major antidepressants, imipramine and fluoxetine, strongly and directly altered GABA-mediated

254 The sensitivity of these effects to fluoxetine suggests that shRNA-mediated knockdown of hip

255 h the selective serotonin reuptake inhibitor fluoxetine suppressed BMP signaling in the adult mouse h

256 These data suggest that fluoxetine suppressed proinflammatory responses, as well

257 In the present study, fluoxetine suppresses the inflammatory response and prot

258 ted with the quantitative GR activity during fluoxetine therapy; this highlights the temporal variabi

259 the most commonly prescribed formulation of fluoxetine, this increased load accounts for the disposa

260 Addition of the antidepressant fluoxetine to the holding water and social interactions

261 A 5-HTT inhibitor, fluoxetine, treated animals also exhibited reduced reste

262 e, but there was no additive effect of CR in fluoxetine-treated mice.

263 longer in OFC-treated patients compared with fluoxetine-treated patients (p<0.001).

264 attern of response: joint treatment > CBT or fluoxetine treatment > placebo treatment.

265 mpal neurogenesis in comparison with chronic fluoxetine treatment (18 mg/kg/day).

266 suggest a neurobiological mechanism by which fluoxetine treatment confers resilience to the chronic s

267 We also found that fluoxetine treatment could disassociate the MeCP2-CREB-B

268 Fluoxetine treatment decreased activations in all three

269 Fluoxetine treatment in adulthood evokes antidepressant

270 The 8 weeks of fluoxetine treatment normalized most of these regions of

271 Chronic fluoxetine treatment produced a significant and selectiv

272 Compared with desipramine, fluoxetine treatment showed a more rapid reduction of HA

273 Compared with desipramine treatment, fluoxetine treatment was associated with a greater reduc

274 Fluoxetine treatment was associated with a larger whole

275 chronic stress, which was partly restored by fluoxetine treatment without affecting glucocorticoid se

276 Fluoxetine treatment, compared to placebo, resulted in s

277 ation between GR (S224) and (S232) following fluoxetine treatment, showing a molecular basis for horm

278 d swim test behavior after social defeat and fluoxetine treatment.

279 hat did not significantly increase following fluoxetine treatment.

280 ; the LTP effects remained blunted following fluoxetine treatment.

281 e elimination of (14)C for carbamazepine and fluoxetine treatments and partial elimination for orlist

282 in a 12-week double-blind placebo-controlled fluoxetine trial.

283 As fluoxetine undergoes stereoselective metabolism within t

284 addition, a synthesis of the antidepressant fluoxetine using remote hydroxylation as a key step is p

285 In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [

286 Three weeks of intervention with fluoxetine was associated with a 5.2% reduction in brain

287 In this observational study, use of fluoxetine was associated with lower BOP percentages and

288 Bioconcentration of fluoxetine was dependent on route of uptake, with filter

289 o-selective analysis showed the high load of fluoxetine was present as a racemic mixture, which is ty

290 The response of the MIP-CP electrode to fluoxetine was remarkably higher than the electrode, mod

291 For efficacy, only fluoxetine was statistically significantly more effectiv

292 both as monotherapy and in combination with fluoxetine, was efficacious and well tolerated in the tr

293 Participants taking fluoxetine were further analyzed for correlation between

294 Relapse/recurrence rates for C-CT and fluoxetine were nearly identical during the 8 months of

295 uding highly selective recognition sites for fluoxetine were synthesized, utilizing precipitation pol

296 Adolescent hamsters administered fluoxetine were tested for offensive aggression using th

297 ribavirin, pyrrolidine dithiocarbamate, and fluoxetine were tested for their capacity to abrogate CV

298 l-specific and cell type-specific effects of fluoxetine, which requires adult hippocampal neurogenesi

299 Worms exposed to 10 mug L(-1), accumulated fluoxetine with a body burden over 270 times greater tha

300 etine metabolite, had a higher affinity than fluoxetine, with an IC50 of 29 muM.